Nirsevimab is protective against RSV infections and coinfections, which suggests there is no replacement of RSV with other viruses post-nirsevimab administration.
The novel treatment consists of a single shot which is made of special proteins called antibodies that bind to the site at ...
Stay home if they are sick until they no longer have a fever for 24 hours without using fever-reducing medicine. Return to ...
Respiratory Syncytial Virus (RSV) is a highly contagious respiratory illness that primarily affects infants and older adults, ...
As we head into the peak of 2025 RSV season, parents are once again facing an uptick in cases, with health experts warning ...
New at-home RSV treatment represents a potential breakthrough in addressing the burden of respiratory diseases, especially in vulnerable pediatric and elderly ...
Flu and RSV are packing a post-holiday one-two punch, sending people into Erie's emergency departments and medical offices ...
Shionogi’s oral antiviral for respiratory syncytial virus (RSV) has met its primary endpoint in a Phase II study.
Shionogi’s respiratory syncytial virus (RSV) antiviral for adults has proven its ability to reduce viral load in a phase 2 ...